The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.
Looking for leads, investment insights, or competitive intelligence?
News about Celgene
Juno's stock is up a staggering 76% since rumors of the Celgene deal emerged last week.
With Juno, Celgene will gain research into a novel class of therapies known as CAR-T.
Former Celgene president Jackie Fouse is joining the unconventional Roivant crew.
The question is: Does this affect medical decision-making?
Hospitals win, health insurers not so much.